We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.76%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$13.8B
AUM Growth
-$581M
(-4%)
Cap. Flow
-$2.79B
Cap. Flow
% of AUM
-20.16%
Top 10 Holdings %
Top 10 Hldgs %
25.18%
Holding
905
New
29
Increased
148
Reduced
448
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$66.4M |
| 2 |
Valero Energy
VLO
|
+$28.9M |
| 3 |
SLB Ltd
SLB
|
+$24.8M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$22.6M |
| 5 |
PepsiCo
PEP
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$182M |
| 2 |
Apple
AAPL
|
+$148M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$90.9M |
| 4 |
Amgen
AMGN
|
+$72.1M |
| 5 |
Tesla
TSLA
|
+$66.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.26% |
| 2 | Technology | 28.78% |
| 3 | Financials | 8.15% |
| 4 | Consumer Discretionary | 7.54% |
| 5 | Industrials | 7.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
4D Molecular Therapeutics
FDMT
$543M
| $3.13M | 0.02% |
173,000
-62,000
| -26% | -$1.14M |
|
402
Sony
SONY
$131B
| $3.1M | 0.02% |
172,345
-42,465
| -20% | -$796K |
|
403
Roper Technologies
ROP
$37.1B
| $3.08M | 0.02% |
6,406
-6,194
| -49% | -$2.8M |
|
404
Corteva
CTVA
$58.6B
| $3.07M | 0.02% |
53,582
-21,957
| -29% | -$1.28M |
|
405
Idexx Laboratories
IDXX
$43.9B
| $3.05M | 0.02% |
6,081
-8,409
| -58% | -$4.03M |
|
406
MSCI
MSCI
$41.5B
| $3.04M | 0.02% |
6,481
-9,581
| -60% | -$4.67M |
|
407
Ross Stores
ROST
$78.1B
| $3.04M | 0.02% |
22,201
-729
| -3% | -$76.6K |
|
408
Skyworks Solutions
SWKS
$9.54B
| $2.99M | 0.02% |
26,991
-5,708
| -17% | -$602K |
|
409
Fastenal
FAST
$54.7B
| $2.98M | 0.02% |
100,948
| – | – |
|
|
PXD
410
DELISTED
Pioneer Natural Resource Co.
PXD
| $2.94M | 0.02% |
14,174
-491
| -3% | -$103K |
|
411
Freeport-McMoran
FCX
$90.2B
| $2.92M | 0.02% |
73,043
+19,977
| +38% | +$761K |
|
412
McKesson
MCK
$99.5B
| $2.92M | 0.02% |
6,822
-7,143
| -51% | -$2.75M |
|
413
Hartford Financial Services
HIG
$38.4B
| $2.91M | 0.02% |
40,338
-56,930
| -59% | -$4M |
|
414
TransUnion
TRU
$14.9B
| $2.86M | 0.02% |
36,449
-105,397
| -74% | -$7.29M |
|
415
International Flavors & Fragrances
IFF
$19.5B
| $2.85M | 0.02% |
35,806
-12,665
| -26% | -$1.09M |
|
416
Atmos Energy
ATO
$29.7B
| $2.83M | 0.02% |
24,335
| – | – |
|
417
Live Nation Entertainment
LYV
$41.7B
| $2.82M | 0.02% |
30,948
-24,112
| -44% | -$1.88M |
|
418
Aflac
AFL
$64.4B
| $2.8M | 0.02% |
40,116
-35,852
| -47% | -$2.4M |
|
419
Array Technologies
ARRY
$848M
| $2.76M | 0.02% |
121,945
-137,764
| -53% | -$2.95M |
|
420
Arthur J. Gallagher & Co
AJG
$65.1B
| $2.73M | 0.02% |
12,456
-12,658
| -50% | -$2.63M |
|
421
PPG Industries
PPG
$26.4B
| $2.73M | 0.02% |
18,422
-1,343
| -7% | -$187K |
|
422
Las Vegas Sands
LVS
$31.6B
| $2.72M | 0.02% |
46,917
+17,594
| +60% | +$1.04M |
|
423
Fidelity National Information Services
FIS
$22.3B
| $2.72M | 0.02% |
49,659
-56,707
| -53% | -$3.12M |
|
424
Autoliv
ALV
$8.76B
| $2.7M | 0.02% |
31,798
-15,941
| -33% | -$1.38M |
|
425
Nucor
NUE
$56.4B
| $2.7M | 0.02% |
16,464
-1,271
| -7% | -$186K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2023 Portfolio in Review
As of Q2 2023, Candriam SCA held 905 positions worth $13.8B, down 4% from $14.4B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Candriam SCA withdrew a net $2.79B in Q2 2023, closing 194 positions and reducing 448 holdings. Its most notable exit was Thomson Reuters, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Vir Biotechnology worth $8.7M.
- Candriam SCA's largest Q2 2023 buy was Vir Biotechnology: 354,645 shares worth $8.7M.
- Candriam SCA added most to Lam Research in Q2 2023, an estimated $66.4M increase.
- Candriam SCA's biggest Q2 2023 reduction was Microsoft, cutting an estimated $182M.
- Candriam SCA fully exited Thomson Reuters in Q2 2023, selling an estimated $19.8M.
- Candriam SCA's ten largest holdings make up 25% of its $13.8B portfolio in Q2 2023.
- Candriam SCA opened 29 new positions and closed 194 in Q2 2023.
- Candriam SCA's portfolio value fell 4% quarter-over-quarter to $13.8B.
Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.